Biocon Pharma Receives USFDA Approval for Liraglutide Injection for Type 2 Diabetes

Biocon Pharma, a wholly owned subsidiary of Biocon, has received USFDA approval for its abbreviated new drug application for Liraglutide injection (gVictoza) in single-patient-use prefilled pens. Indicated for treating insufficiently controlled type 2 diabetes in patients aged 10 and above, this approval follows an earlier clearance for Liraglutide injection (gSaxenda). The company highlighted this as an addition to its portfolio of complex drug products, with recent financial results showing increased profit and sales.